• EMA approves Cimzia for use in treating plaque psoriasis pharmafile
    July 06, 2018
    The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.
PharmaSources Customer Service